Detail akcie Aclaris Therap online

Business Summary: Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Financial Summary: BRIEF: For the six months ended 30 June 2025, Aclaris Therapeutics Inc revenues decreased 37% to $3.2M. Net loss increased 9% to $30.5M. Revenues reflect Therapeutics segment decrease of 40% to $2.3M, Contract Research segment decrease of 31% to $887K. Higher net loss reflects Therapeutics segment loss increase of 23% to $25.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.25.